Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-000195-98-NL
EUCTR2015-000195-98-NLActive, not recruitingPhase 1

A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation - HOVON 134 MF

HOVON Foundation0 sites70 target enrollmentStarted: February 3, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
70
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •-Patients with a confirmed diagnosis of post-ET, post-PV or primary myelofibrosis (Appendix A)
  • •-Intermediate-2 or high-risk according to DIPSS plus (Appendix F)
  • •-Age 18-70 years inclusive
  • •-WHO performance status 0-2 (Appendix C)
  • •Platelet count = 25 × 109/L without platelet support within 2 weeks before study entry.
  • •-All men and women of childbearing potential must agree to use adequate contraception during the study
  • •-Written informed consent
  • •-Patient is capable of giving informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 40
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

  • •- Patients who have been treated with pacritinib as their previous JAK2 inhibitor treatment cannot participate in this study.
  • •- Previous treatment with JAK2 inhbitors, other than pacritinib, is allowed with the exception of high dose ruxolitinib (above 10 mg BID). For these patients taper the dose to 10 mg BID or lower at least 2 weeks before pacritinib treatment is allowed.
  • •- Any GI or metabolic condition (e.g. inflammatory or chronic functional bowel disorder such as Crohn’s Disease, Inflammatory Bowel Disease, chronic diarrhea or constipation) that could interfere with absorption of oral medication
  • •- Left ventricular cardiac ejection fraction of = 45% by echocardiogram or multigated acquisition (MUGA) scan
  • •- Impaired liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), >3 × the upper limit of normal (ULN) (AST/ALT >5 × ULN if transaminase elevation is related to MF), direct bilirubin >4× ULN, and creatinine clearance ? 40 ml/min.
  • •-Experimental treatment within four weeks before inclusion for PMF, Post-PV, or Post-ET MF
  • •-Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D)
  • •- Treatment with a potent strong CYP3A4 inhibitor or a strong cytochrome P450 (CYP450) inducer within the last 2 weeks
  • •- Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of =100 mg per day, within the last 2 weeks
  • •- New York Heart Association Class II, III, or IV congestive heart failure
  • •- QTc prolongation >450 ms as assessed by ECG and corrected by Federicia method or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval)
  • •- Significant recent bleeding history defined as NCI CTCAE grade =2 within the last 3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)
  • •- Any history of CTCAE grade =2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the principal investigator, if stable and unlikely to affect patient safety
  • •- Any history of CTCAE grade =2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the principal investigator, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety
  • •-Patients with active, uncontrolled infections
  • •-Patients known to be HIV(human immunodeficiency virus)-positive
  • •-Active hepatitis A, B or C
  • •-History of active malignancy during the past 3 years, except basal carcinoma of the skin or stage 0 cervical carcinoma
  • •-Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, cancer, etc.)
  • •-Pregnant or breastfeeding women
  • •-Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Investigators

Sponsor
HOVON Foundation

Similar Trials

Active, not recruiting
Phase 1
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantatioPrimary myelofibrosisPolycythemia veraEssential thrombocytosisMedDRA version: 20.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-000195-98-BEHOVON Foundation70
Recruiting
Phase 2
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantatioMyelofibrosisprimary myelofibrosis
NL-OMON47477HOVO65
Not yet recruiting
Not Applicable
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantatio
NL-OMON21596HOVON<br>VU University Medical Center,<br>P.O.Box 7057<br>1007 MB Amsterdam<br>The Netherlands<br>tel: +31 20 4442124<br>tel: +31 20 4449086<br>Fax: +31 20 444356670
Terminated
Phase 2
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
NCT02226172Pfizer21
Completed
Phase 2
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaEssential ThrombocythemiaPolycythemia VeraPrimary Myelofibrosis
NCT00047190National Cancer Institute (NCI)35